Avelumab and Merkel Cell Carcinoma: Causation or Therapeutic Association?
From General Health to Targeted Exposure Analysis
For decades, public health communication has centered on general wellness principles, emphasizing lifestyle factors such as diet, exercise, and routine screenings to mitigate disease risk. This broad foundation has served populations well, fostering awareness of common health threats and preventive behaviors. Within this legacy framework, discussions of cancer have typically focused on modifiable risk factors like smoking or sun exposure, with therapeutic interventions considered only after diagnosis. The transition from this generalized health context to a more specialized occupational exposure concern requires a shift in perspective—from passive health maintenance to active scrutiny of specific pharmaceutical agents encountered in clinical or manufacturing settings. Avelumab, a monoclonal antibody used in oncology, represents a point where general health awareness meets targeted exposure analysis. While the legacy theme addresses cancer broadly, the emerging query narrows focus to avelumab’s potential association with Merkel cell carcinoma, a rare skin cancer. This pivot does not imply causation but rather acknowledges that occupational or therapeutic exposure to such agents warrants careful monitoring. The bridge concept here is the recognition that substances introduced for therapeutic benefit may, under certain conditions, present risks that fall outside traditional public health messaging. Thus, the transition moves from general health information to a specific, evidence-informed inquiry into avelumab exposure and its possible link to Merkel cell carcinoma, setting the stage for a focused risk assessment.
Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma
Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is a highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Chronic exposure to ultraviolet light and the Merkel cell polyoma virus are established risk factors for MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Despite advances in systemic therapy, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Causation vs. Therapeutic Association: Evidence Review
The mechanistic pathway linking avelumab to MCC is not one of causation but rather of therapeutic targeting. Avelumab is designed to treat MCC by blocking PD-L1, thereby reactivating the immune system against tumor cells. However, immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This indicates that while avelumab can trigger immune-related complications, these are distinct from the primary disease being treated. For patients who become refractory to avelumab, alternative treatment options are limited. In Europe, approved systemic therapies for MCC are restricted to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, combined ipilimumab plus nivolumab has shown efficacy. In a multicenter study of the prospective skin cancer registry ADOREG, response rates to PD-1/PD-L1 inhibition in metastatic MCC were up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). In a retrospective study of five patients treated at three German academic sites, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study confirmed that ipilimumab plus nivolumab is used in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Risk Context and Monitoring Considerations
Regarding risk anchors, the adequacy of warnings about avelumab and MCC is centered on its approved use as a treatment, not as a causative agent. The evidence does not indicate that avelumab causes MCC; rather, it is a therapeutic agent for the disease. Causation-related considerations for affected patients focus on the risk of immune-related adverse events and the potential for disease progression despite treatment. The timeline between exposure to avelumab and documented harm is variable. For immune-related adverse events, such as sarcoidosis reactivation, the onset can occur during treatment, as seen in the case report where hypercalcemia developed during avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). For disease progression, the timeline is defined by clinical response assessments, with approximately 50% of patients progressing on ICI therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The JAVELIN Merkel 200 trial demonstrated that objective responses occur in about one-third of patients, indicating that a significant proportion do not respond or progress (https://pubmed.ncbi.nlm.nih.gov/29799096/). In summary, avelumab is a targeted therapy for metastatic MCC, not a causative agent. Its use is associated with immune-related adverse events and variable response rates. For patients who become refractory, alternative ICI combinations such as ipilimumab plus nivolumab may offer benefit. The evidence underscores the importance of monitoring for irAEs and disease progression during avelumab treatment.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is a therapeutic agent used to treat Merkel cell carcinoma (MCC). It is an immune checkpoint inhibitor that targets PD-L1 to reactivate the immune system against tumor cells. The evidence does not indicate that avelumab causes MCC; rather, it is approved for the treatment of metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).
What are the risks associated with avelumab treatment?
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as hypercalcemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, approximately 50% of patients with advanced MCC may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Monitoring for irAEs and disease progression is essential during treatment.
What treatment options exist for patients who become refractory to avelumab?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.